| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3904416 | Urology | 2008 | 5 Pages |
Abstract
The adjuvant use of paclitaxel and estramustine in resected high-risk prostate cancer patients is feasible and well tolerated. Adjuvant cytotoxic chemotherapy deserves further investigation with randomized studies.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Jeremy P. Cetnar, S. Bruce Malkowicz, Steven C. Palmer, Alan J. Wein, David J. Vaughn,